All In Biotech

Drug Trial Radar · NCT07519499

Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 Injection

Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 Injection in Trial Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Apr 1, 2026

Primary completion

Dec 1, 2027

Study completion Feb 1, 2028

Sponsor

Sponsor type
Industry
First posted
Apr 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-parallel-controlled, two-stage design, Phase II clinical study. This study is divided into two stages. Stage 1 (Phase IIa) has a dosing duration of 24 weeks (treatment period of 28 weeks) and aims to preliminarily evaluate the efficacy, safety, PK characteristics, and immunogenicity of XKH001 Injection in trial participants with moderate to severe COPD. Stage 2 (Phase IIb) has a dosing duration of 48 weeks (treatment period of 52 weeks) and aims to further evaluate the efficacy, safety, PK characteristics, and immunogenicity of XKH001 Injection in trial participants with moderate to severe COPD.

Conditions

  • COPD

Interventions

  • XKH001InjectionDrug

    XKH001, developed by Zhejiang Kanova Biopharmaceutical Co., Ltd., is a recombinant anti-IL-25 humanized IgG1 monoclonal antibody (mAb) composed of two identical light chains and two identical heavy chains linked by disulfide bonds. Each light chain consists of 215 amino acids, and each heavy chain consists of 455 amino acids, for a total of 1340 amino acids. XKH001 has a total of 16 pairs of disulfide bonds, including 4 pairs of intra-light chain disulfide bonds, 8 pairs of intra-heavy chain disulfide bonds, 2 pairs of light-heavy interchain disulfide bonds, and 2 pairs of heavy-heavy interchain disulfide bonds. XKH001 has an N-glycosylation site at N305 of the heavy chain, with G0F oligosaccharide being the major form of N-glycosylation.

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Outcome1Time frame: Week 36
  2. Primary Outcome2Time frame: Week 28

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.